Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Norman Burns

Neurology Rochester Hills, MI Medical Doctor

NPI 1891793402 CMS profile 358613

3950 S Rochester Rd, Suite 1200, Rochester Hills, MI 48307

Open in the dashboard

General payments

$32,680

2,008 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Norman Burns of Rochester Hills, MI is reported in the CMS Open Payments database as having received $32,680 across 2,008 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,954 307
2024 General $5,579 340
2023 General $5,843 376
2022 General $5,178 348
2021 General $3,459 236
2020 General $4,199 137
2019 General $3,469 264

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Norman Burns
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Norman Burns were reported at $4,954. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Norman Burns Neurology median Middle half National median
2019 $3,469 $474 $118–$2,177 $163
2020 $4,199 $367 $82–$2,309 $114
2021 $3,459 $438 $104–$2,547 $132
2022 $5,178 $442 $103–$2,388 $149
2023 $5,843 $464 $119–$2,312 $160
2024 $5,579 $468 $119–$2,323 $164
2025 $4,954 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $2,731 40 payments
  2. Novartis Pharmaceuticals Corporation $2,484 272 payments
  3. AbbVie, Inc. $1,992 152 payments
  4. Biogen, Inc. $1,915 98 payments
  5. UCB, Inc. $1,768 131 payments
  6. Celgene Corporation $1,553 103 payments
  7. EMD Serono, Inc. $1,362 79 payments
  8. Supernus Pharmaceuticals, Inc. $1,187 86 payments
  9. Genzyme Corporation $966 54 payments
  10. Neurocrine Biosciences, Inc. $899 43 payments
  11. Other $15,821 950 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $30,088 1,990 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,612 8 payments
  3. Travel and Lodging $545 2 payments
  4. Education $435 8 payments
Products named General payments · program years 2019–2025
  1. UBRELVY Neuroscience $2,421 14 payments
  2. ZEPOSIA $1,631 105 payments
  3. KESIMPTA $1,284 153 payments
  4. Briviact $1,178 82 payments
  5. TYSABRI $983 51 payments
  6. QULIPTA $966 67 payments
  7. TROKENDI XR $944 70 payments
  8. INGREZZA $820 38 payments
  9. UBRELVY Neuroscience $792 70 payments
  10. BRIUMVI $697 28 payments
  11. Other $22,050 1,427 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 88 drugs

Part D claims

5,348

Median for Neurology: 833

Drug cost

$982,730

Median for Neurology: $202,670

Branded share of claims

28%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Aubagio Teriflunomide Brand 13 $119,796
Fingolimod Fingolimod Hcl Brand 25 $96,400
Briviact Brivaracetam Brand 47 $74,563
Nurtec Odt Rimegepant Sulfate Brand 43 $70,078
Ubrelvy Ubrogepant Brand 50 $68,815
Copaxone Glatiramer Acetate Brand 11 $63,122
Nuplazid Pimavanserin Tartrate Brand 12 $55,844
Aimovig Autoinjector Erenumab-Aooe Brand 67 $51,876
Aptiom Eslicarbazepine Acetate Brand 28 $45,842
Emgality Pen Galcanezumab-Gnlm Brand 53 $45,577

The 10 drugs with the highest cost, of 88 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$121,991

Medicare's payments for the services billed

Medicare patients

503

Average age 73

Services billed

4,812

266 women, 237 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 44%
Diabetes 38%
Depression 34%
Alzheimer's or dementia 34%
Chronic kidney disease 31%
Atrial fibrillation 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 51 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KESIMPTA
$490 — —
ZEPOSIA
$411 — —
BRIUMVI
$290 — —
INGREZZA
$205 — —
PURIFIED CORTROPHIN GEL
$187 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 51 with Patron

Records

2,008 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record